These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32046073)

  • 21. Classification of Parkinson's Disease in Patch-Based MRI of Substantia Nigra.
    Hussain SS; Degang X; Shah PM; Islam SU; Alam M; Khan IA; Awwad FA; Ismail EAA
    Diagnostics (Basel); 2023 Aug; 13(17):. PubMed ID: 37685365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiomic Features of the Nigrosome-1 Region of the Substantia Nigra: Using Quantitative Susceptibility Mapping to Assist the Diagnosis of Idiopathic Parkinson's Disease.
    Cheng Z; Zhang J; He N; Li Y; Wen Y; Xu H; Tang R; Jin Z; Haacke EM; Yan F; Qian D
    Front Aging Neurosci; 2019; 11():167. PubMed ID: 31379555
    [No Abstract]   [Full Text] [Related]  

  • 23. Radiogenomics of lower-grade gliomas: machine learning-based MRI texture analysis for predicting 1p/19q codeletion status.
    Kocak B; Durmaz ES; Ates E; Sel I; Turgut Gunes S; Kaya OK; Zeynalova A; Kilickesmez O
    Eur Radiol; 2020 Feb; 30(2):877-886. PubMed ID: 31691122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuromelanin-sensitive magnetic resonance imaging features of the substantia nigra and locus coeruleus in de novo Parkinson's disease and its phenotypes.
    Wang J; Li Y; Huang Z; Wan W; Zhang Y; Wang C; Cheng X; Ye F; Liu K; Fei G; Zeng M; Jin L
    Eur J Neurol; 2018 Jul; 25(7):949-e73. PubMed ID: 29520900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuromelanin-sensitive MRI of the substantia nigra: An imaging biomarker to differentiate essential tremor from tremor-dominant Parkinson's disease.
    Wang J; Huang Z; Li Y; Ye F; Wang C; Zhang Y; Cheng X; Fei G; Liu K; Zeng M; Zhong C; Jin L
    Parkinsonism Relat Disord; 2019 Jan; 58():3-8. PubMed ID: 30037690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Parkinson's disease without nigral degeneration: a pathological correlate of scans without evidence of dopaminergic deficit (SWEDD)?
    Ling H; Kearney S; Yip HL; Silveira-Moriyama L; Revesz T; Holton JL; Strand C; Davey K; Mok KY; Polke JM; Lees AJ
    J Neurol Neurosurg Psychiatry; 2016 Jun; 87(6):633-41. PubMed ID: 26209716
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vocal Feature Extraction-Based Artificial Intelligent Model for Parkinson's Disease Detection.
    Hoq M; Uddin MN; Park SB
    Diagnostics (Basel); 2021 Jun; 11(6):. PubMed ID: 34208330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Automatic Classification on Multi-Modal MRI Data for Diagnosis of the Postural Instability and Gait Difficulty Subtype of Parkinson's Disease.
    Gu Q; Zhang H; Xuan M; Luo W; Huang P; Xia S; Zhang M
    J Parkinsons Dis; 2016 May; 6(3):545-56. PubMed ID: 27176623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved Automatic Morphology-Based Classification of Parkinson's Disease and Progressive Supranuclear Palsy.
    Talai AS; Ismail Z; Sedlacik J; Boelmans K; Forkert ND
    Clin Neuroradiol; 2019 Dec; 29(4):605-614. PubMed ID: 30218110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson's patients.
    Du G; Lewis MM; Sica C; He L; Connor JR; Kong L; Mailman RB; Huang X
    Mov Disord; 2018 Sep; 33(9):1423-1431. PubMed ID: 29756399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of collapsin response mediator protein 4 suppresses dopaminergic neuron death in an 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
    Tonouchi A; Nagai J; Togashi K; Goshima Y; Ohshima T
    J Neurochem; 2016 Jun; 137(5):795-805. PubMed ID: 26991935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Age and Parkinson's disease-related neuronal death in the substantia nigra pars compacta.
    Eriksen N; Stark AK; Pakkenberg B
    J Neural Transm Suppl; 2009; (73):203-13. PubMed ID: 20411779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Automated neuromelanin imaging as a diagnostic biomarker for Parkinson's disease.
    Castellanos G; Fernández-Seara MA; Lorenzo-Betancor O; Ortega-Cubero S; Puigvert M; Uranga J; Vidorreta M; Irigoyen J; Lorenzo E; Muñoz-Barrutia A; Ortiz-de-Solorzano C; Pastor P; Pastor MA
    Mov Disord; 2015 Jun; 30(7):945-52. PubMed ID: 25772492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detecting dopaminergic neuronal degeneration using diffusion tensor imaging in a rotenone-induced rat model of Parkinson's disease: fractional anisotropy and mean diffusivity values.
    Liu LX; Du D; Zheng T; Fang Y; Chen YS; Yi HL; He QY; Gao DW; Shi QL
    Neural Regen Res; 2017 Sep; 12(9):1485-1491. PubMed ID: 29089995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alterations of the nigrostriatal pathway in a 6-OHDA rat model of Parkinson's disease evaluated with multimodal MRI.
    Perlbarg V; Lambert J; Butler B; Felfli M; Valabrègue R; Privat AL; Lehéricy S; Petiet A
    PLoS One; 2018; 13(9):e0202597. PubMed ID: 30188909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Free-water imaging in Parkinson's disease and atypical parkinsonism.
    Planetta PJ; Ofori E; Pasternak O; Burciu RG; Shukla P; DeSimone JC; Okun MS; McFarland NR; Vaillancourt DE
    Brain; 2016 Feb; 139(Pt 2):495-508. PubMed ID: 26705348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative assessment of iron deposition in the midbrain using 3D-enhanced T2 star weighted angiography (ESWAN): a preliminary cross-sectional study of 20 Parkinson's disease patients.
    Wang C; Fan G; Xu K; Wang S
    Magn Reson Imaging; 2013 Sep; 31(7):1068-73. PubMed ID: 23746648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Classifying Parkinson's Disease Based on Acoustic Measures Using Artificial Neural Networks.
    Berus L; Klancnik S; Brezocnik M; Ficko M
    Sensors (Basel); 2018 Dec; 19(1):. PubMed ID: 30577548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T2-Imaging Changes in the Nigrosome-1 Relate to Clinical Measures of Parkinson's Disease.
    Fu KA; Nathan R; Dinov ID; Li J; Toga AW
    Front Neurol; 2016; 7():174. PubMed ID: 27812347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature.
    Péran P; Cherubini A; Assogna F; Piras F; Quattrocchi C; Peppe A; Celsis P; Rascol O; Démonet JF; Stefani A; Pierantozzi M; Pontieri FE; Caltagirone C; Spalletta G; Sabatini U
    Brain; 2010 Nov; 133(11):3423-33. PubMed ID: 20736190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.